Precision oncology’s translation gap, Can molecular tumor boards bridge it?

Article excerpt

by Margaret M. Byrne, Jill M. Kolesar Precision oncology is revolutionizing cancer care, but isn’t reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs? Molecular tumor boards translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. In this Perspective, Margaret Byrne and Jill Kolesar discuss how we may feasibly and equitably expand the use of MTBs.